{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T13:35:38Z","timestamp":1791207338572,"version":"4.1.0"},"reference-count":65,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2025,3,16]],"date-time":"2025-03-16T00:00:00Z","timestamp":1742083200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>Despite the development of novel treatments, multiple myeloma (MM) and light\u2010chain (AL) amyloidosis remain incurable diseases. BCL2 inhibitors are a class of drugs under development for plasma cell disorders, with strong data supporting their use, particularly in patients with MM and AL amyloidosis harbouring the t(11;14). Venetoclax, the most extensively studied BCL2\u2010specific inhibitor, was initially designed and evaluated for other malignant blood disorders. However, it has since shown promising efficacy in both randomized and real\u2010world studies for MM and AL amyloidosis, either as a monotherapy or in combination with other agents. Nonetheless, toxicity concerns have been raised, underscoring the need for careful patient selection and precise dose optimization. Additionally, other BCL2\u2010targeting drugs are under investigation in preclinical and clinical studies. This review focuses on the current role of BCL2 inhibitors in the treatment landscape of MM and AL amyloidosis.<\/jats:p>","DOI":"10.1111\/bjh.20046","type":"journal-article","created":{"date-parts":[[2025,3,16]],"date-time":"2025-03-16T20:14:11Z","timestamp":1742156051000},"page":"1285-1296","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["<scp>BCL2<\/scp>\n                    inhibition for multiple myeloma and\n                    <scp>AL<\/scp>\n                    amyloidosis"],"prefix":"10.1111","volume":"206","author":[{"given":"Lorenzo","family":"Cani","sequence":"first","affiliation":[{"name":"Hematology and Medical Oncology Winship Cancer Institute, Emory University  Atlanta Georgia USA"},{"name":"Division of Hematology University of Torino  Torino Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikas A.","family":"Gupta","sequence":"additional","affiliation":[{"name":"Hematology and Medical Oncology Winship Cancer Institute, Emory University  Atlanta Georgia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5687-6429","authenticated-orcid":false,"given":"Jonathan L.","family":"Kaufman","sequence":"additional","affiliation":[{"name":"Hematology and Medical Oncology Winship Cancer Institute, Emory University  Atlanta Georgia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,3,16]]},"reference":[{"key":"e_1_2_14_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2011.02.013"},{"key":"e_1_2_14_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1210220"},{"key":"e_1_2_14_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2297"},{"key":"e_1_2_14_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2019.100643"},{"key":"e_1_2_14_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70442-5"},{"key":"e_1_2_14_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.329"},{"key":"e_1_2_14_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00512"},{"key":"e_1_2_14_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/emboj.2011.307"},{"key":"e_1_2_14_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2010.01.025"},{"key":"e_1_2_14_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/cdd.2017.179"},{"key":"e_1_2_14_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.184"},{"key":"e_1_2_14_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V100.1.194"},{"key":"e_1_2_14_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020007899"},{"key":"e_1_2_14_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023020276"},{"key":"e_1_2_14_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15051-z"},{"key":"e_1_2_14_17_1","doi-asserted-by":"publisher","DOI":"10.1158\/2767-9764.CRC-23-0350"},{"key":"e_1_2_14_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2015.464"},{"key":"e_1_2_14_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.350"},{"key":"e_1_2_14_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-10-745059"},{"key":"e_1_2_14_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00710-9"},{"key":"e_1_2_14_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-33461-z"},{"key":"e_1_2_14_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0374-8"},{"key":"e_1_2_14_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-127593"},{"key":"e_1_2_14_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-10363-1"},{"key":"e_1_2_14_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-06-788786"},{"key":"e_1_2_14_27_1","doi-asserted-by":"publisher","DOI":"10.2147\/BLCTT.S245191"},{"key":"e_1_2_14_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26083"},{"key":"e_1_2_14_29_1","unstructured":"AbbVie.Presents results from phase 3 CANOVA study of venetoclax in patients with relapsed or refractory multiple myeloma. News Release.2023. [cited 2023 Oct 5].https:\/\/tinyurl.com\/32j9dekf"},{"key":"e_1_2_14_30_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.7510"},{"key":"e_1_2_14_31_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-0676"},{"key":"e_1_2_14_32_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-06-788323"},{"key":"e_1_2_14_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30525-8"},{"key":"e_1_2_14_34_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020004146"},{"key":"e_1_2_14_35_1","doi-asserted-by":"crossref","unstructured":"KaufmanJL GasparettoC KovacsovicsT.First results from the randomized portion of a phase 2 study of venetoclax plus carfilzomib\u2010dexamethasone vs carfilzomib\u2010dexamethasone in patients with t(11;14)\u2010positive relapsed\/refractory multiple myeloma. Presented at: 20th International Myeloma Society Annual Meeting; September 27\u201030 2023; Athens Greece.","DOI":"10.1016\/S2152-2650(23)01596-3"},{"key":"e_1_2_14_36_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00443"},{"key":"e_1_2_14_37_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-180766"},{"key":"e_1_2_14_38_1","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/842945"},{"key":"e_1_2_14_39_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-19-0759"},{"key":"e_1_2_14_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2021.07.029"},{"key":"e_1_2_14_41_1","first-page":"980","article-title":"Venetoclax salvage therapy in relapsed\/refractory multiple myeloma","volume":"109","author":"Steinhardt MJ","year":"2024","journal-title":"Haematologica"},{"key":"e_1_2_14_42_1","doi-asserted-by":"publisher","DOI":"10.3389\/pore.2022.1610276"},{"key":"e_1_2_14_43_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26064"},{"key":"e_1_2_14_44_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-021-04555-3"},{"key":"e_1_2_14_45_1","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2024.2309873"},{"key":"e_1_2_14_46_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-178735"},{"key":"e_1_2_14_47_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019002762"},{"key":"e_1_2_14_48_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2028631"},{"key":"e_1_2_14_49_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27177"},{"key":"e_1_2_14_50_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.3683"},{"key":"e_1_2_14_51_1","doi-asserted-by":"publisher","DOI":"10.1080\/13506129.2020.1778461"},{"key":"e_1_2_14_52_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.57.4947"},{"key":"e_1_2_14_53_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-166224"},{"key":"e_1_2_14_54_1","doi-asserted-by":"publisher","DOI":"10.1080\/13506129.2024.2366806"},{"key":"e_1_2_14_55_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15061710"},{"key":"e_1_2_14_56_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaq1240"},{"key":"e_1_2_14_57_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-142656"},{"key":"e_1_2_14_58_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-158617"},{"key":"e_1_2_14_59_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-188122"},{"key":"e_1_2_14_60_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26207"},{"key":"e_1_2_14_61_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16454"},{"key":"e_1_2_14_62_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2736"},{"key":"e_1_2_14_63_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17380"},{"key":"e_1_2_14_64_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-0321-6"},{"key":"e_1_2_14_65_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-00397-w"},{"key":"e_1_2_14_66_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-183030"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.20046","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T09:43:26Z","timestamp":1765791806000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.20046"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,16]]},"references-count":65,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["10.1111\/bjh.20046"],"URL":"https:\/\/doi.org\/10.1111\/bjh.20046","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,16]]},"assertion":[{"value":"2024-11-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-28","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}